

Hannah Storm, Award-Winning Broadcaster and DCIS Patient Advocate, Partners with PreludeDx to Share How the DCISionRT Test Gave Her Confidence in Her Treatment Decision

LAGUNA HILLS, Calif., February 12, 2025 /PRNewswire/-- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, an Emmy award-winning sports broadcaster, producer and director. Storm, who was diagnosed with ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, in early 2024, is a champion of advancing women's health education and promoting informed decision-making in breast cancer screening, testing, and treatment.

Soon after her diagnosis, Storm's physician team ordered PreludeDx's DCISionRT®, the only risk assessment test that predicts radiation therapy (RT) benefit in DCIS patients, to be run on her tumor tissue.

The personalized results from Storm's DCISionRT test showed that her risk level for recurrence within 10 years was very low, and that she would not benefit from radiation therapy. Together with her physician team, they made a shared decision to safely forego RT.

"The DCISionRT test was the bedrock of my treatment plan," Storm says. "The low-risk result indicated that radiation would not benefit me based on the assessment of my tumor biology, and that my lumpectomy alone would be enough. I was grateful that I did not need to go through radiation therapy and the results immediately reduced my anxiety. DCISionRT gave me back tremendous confidence and control in managing my breast cancer."

Storm will work with PreludeDx to raise awareness about the importance of precision diagnostics in personalizing treatment decisions. She encourages every DCIS patient to ask their physicians to order DCISionRT, so they understand their risk and benefit from radiation therapy. DCISionRT empowers women and their physicians to make a better and more informed treatment decision. The partnership will focus on making sure all women, regardless of their socioeconomic status or geographic location, have access to advanced diagnostic testing for breast cancer. Storm will use her social media platform and join the PreludeDx team to educate women about the importance of screening, early detection and personalized treatment approaches.

"Hannah Storm's commitment to women's health education and advocacy aligns perfectly with our mission," says Dan Forche, CEO of PreludeDx. "As a breast cancer survivor, her dedication to helping others makes her an ideal partner in our efforts to improve patient outcomes through precision diagnostics."

The collaboration launches as Storm recently earned the prestigious Pat Summerall Award at the *Legends for Charity* event benefiting St. Jude Children's Research Hospital, which recognizes her accomplishments in sports broadcasting and philanthropic impact in the community.

DCIS represents approximately 20% of all newly diagnosed breast cancers and presents a unique challenge in treatment decision-making. Historically, the standard of care for most women diagnosed with DCIS has been breast-conserving surgery (BCS), with or without adjuvant radiation therapy. Reliance on using clinical and pathologic factors alone to make RT decisions has led to concerns about both over- and undertreatment in DCIS.

About DCISionRT for Breast DCIS

DCISionRT is the *only* risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman's individual tumor biology along with other pathologic risk factors to provide a personalized recurrence risk. The test provides a Decision Score™ that identifies a woman's risk as low or elevated. Unlike other risk assessment tools, the DCISionRT test combines protein expression from seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions between individual factors in order to better interpret complex biological information. DCISionRT's intelligent reporting provides a woman's recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.

About PreludeDx

PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the healthcare system. Before making a treatment decision, Know Your Risk™. PreludeDx is a Fjord Ventures portfolio company.

For more information on how PreludeDx is making a difference for patients, please visit the Company's website: <https://preludedx.com> and follow us on [LinkedIn](#) , [Instagram](#) and [Facebook](#).

PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, DecisionTree, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in the United States and foreign countries.

Media Contact

Chris Emery
cemery@preludedx.com

Investor Contact

Andrew Wade
awade@preludedx.com